Adverse effects of local or systemic application of rapamycin for the prevention of neointimal hyperplasia [6] (multiple letters)

Annals of Thoracic Surgery

Volumn 79, Issue 6, 2005, Pages 2201-2202

  Walpoth, Beat H ^a   Schachner, Thomas ^b   Laufer, Guenther ^b   Bonatti, Johannes ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

ARTERY INTIMA PROLIFERATION; ARTERY THROMBOSIS; BLOOD VESSEL GRAFT; DRUG ELUTING STENT; DRUG MEGADOSE; IN-STENT RESTENOSIS; KIDNEY GRAFT; LETTER; MATERIAL COATING; NONHUMAN; PRIORITY JOURNAL; WEIGHT REDUCTION;

EID: 20444424989     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2004.08.040     Document Type: Letter

References (4)

1. T. Schachner Y. Zou Y. Oberhuber Local application of rapamycin inhibits neointimal hyperplasia in experimental vein grafts Ann Thorac Surg 77 2004 1580 1585
2. B.H. Walpoth M. Pavlicek B. Celik Prevention of neointimal proliferation by immunosuppression in synthetic vascular grafts Eur J Cardiothorac Surg 19 4 2001 487 492
3. R. Virmani G. Guagliumi A. Farb Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent Circulation 109 2004 38 42
4. FDA advises physicians of adverse events associated with Cordis Cypher coronary stents. US Food and Drug Administration Public Health Web Notification, October 29, 2003:T03-T71 ( http://www.fda.gov/cdrh/safety/cypher3.html ).